The VEF underwent review and finalization by the INT2GRATE’s multidisciplinary core committee, which includes board-certified medical geneticists specializing in cancer genetics and tumor profiling, clinicians and genetic counselors with expertise in hereditary cancer diagnostics, including VHL, and board-certified pathologists with expertise in molecular pathology and tumor profiling. The gene discussed is VHL; the disease is hereditary cancer.